This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.
The resolved identity has matching regulatory evidence in 7 of 13 indexed market datasets: 7 country records and 1 EU Annex records. Every result and evidence gap is listed below.
A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.
6-Chloro-2-(6-chloro-4-methyl-3-oxobenzo[b]thien-2(3H)-ylidene)-4-methylbenzo[b]thiophene-3(2H)-one
Inventory restriction note: IV/100
Each compound below is connected through an exact CosIng ingredient-name match and an exact PubChem synonym match. It is not inferred from a partial or similar name.
Exact CosIng INCI name equals a PubChem synonym · Checked 2026-08-31
Open each matched record for its scope, concentration, conditions, warnings and official source version.
Swipe or scroll horizontally to see dataset coverage and next actions.
| Market | Result | Records | Dataset | Meaning / next action |
|---|---|---|---|---|
| European Union EU | Conditional positive-list match | 1Open record 1 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | Review every linked record and exact conditions. |
| Great Britain GB | Prohibited | 1Open record 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | Review every linked record and exact conditions. |
| Canada CA | No local match | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Prohibited | 2Open record 1Open record 2 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | Review every linked record and exact conditions. |
| ASEAN ASEAN | Prohibited | 1Open record 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Review every linked record and exact conditions. |
| China CN | No local match | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | No local match | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | No local match | 0 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Korean source wording is canonical and other positive lists/notices may still apply to the formulation. |
| United States US | No local match | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | No local match | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | Prohibited | 1Open record 1 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | Review every linked record and exact conditions. |
| India IN | Prohibited | 1Open record 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | Review every linked record and exact conditions. |
| Saudi Arabia SA | Prohibited | 1Open record 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | Review every linked record and exact conditions. |
These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Research this identityUNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Research this identityHazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Research this identityChemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Research this identityREL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Research this identityGateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Research this identityDTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Research this identityMatch the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.
Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.
Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.
Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.
Open official Decision